The T-cell lymphomas, representing approximately 10% of all non-Hodgkin lymphomas, are heterogeneous, poorly understood, and generally associated with a dismal prognosis. The cell of origin for most T-cell lymphoproliferative disorders has remained elusive and represents a barrier to further advances in this field. Normal T cells, under the influence of specific transcription factors, differentiate into functionally disinct populations following antigenic stimulation. For example, GATA-binding protein 3 (GATA-3) is a transcription factor that controls T-cell differentiation into T helper type 2 (Th2) cells. We have shown that myeloid-derived cells are regulated by cytokines transcriptionally regulated by GATA-3 and that these cells, including lymphoma-associated macrophages, promote the growth and survival of malignant T cells. Therefore, we hypothesized that a subset of T-cell lymphomas may be Th2-cell derived and regulate their microenvironment by producing cytokines that are transcriptionally regulated by GATA-3. In support of this hypothesis, we have found that a subset of T-cell lymphomas with an especially poor prognosis expresses GATA-3 and that its expression is associated with clinical and biologic characteristics resembling Th2 cells. Therefore, we aim to test the hypothesis that GATA-3 expression identifies a previously uncharacterized subset of T-cell lymphomas that exploit a GATA-3 driven transcriptional program to regulate lymphoma-associated macrophages within the tumor microenvironment. This hypothesis may support a novel paradigm in tumor biology with implications that extend beyond the T-cell lymphomas. Namely, transcriptional programs that determine cell lineage and differentiation in malignant cells may regulate stromal cells within the tumor microenvironment that are required for tumor growth.
Non-Hodgkin lymphoma is the seventh most common cancer in the United States. Ten to fifteen percent of these are T-cell derived. Unfortunately, the T-cell lymphomas are poorly understood, increasing in incidence, and are associated with a poor prognosis. Improved understanding of their pathogenesis is needed in order to develop better therapeutic strategies.
|Zhang, Janie Y; Briski, Robert; Devata, Sumana et al. (2018) Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am J Hematol 93:394-400|
|Murga-Zamalloa, Carlos; Polk, Avery; Hanel, Walter et al. (2017) Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. Oncotarget 8:114474-114480|
|Wang, Tianjiao; Lu, Ye; Polk, Avery et al. (2017) T-cell Receptor Signaling Activates an ITK/NF-?B/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy. Clin Cancer Res 23:2506-2515|
|Boonstra, Philip S; Polk, Avery; Brown, Noah et al. (2017) A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas. Am J Hematol 92:1287-1294|
|Friedman, Daphne R; Sibley, Alexander B; Owzar, Kouros et al. (2016) Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. Am J Hematol 91:687-91|
|Wilcox, Ryan A (2016) Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91:151-65|
|Phillips, Tycel; Devata, Sumana; Wilcox, Ryan A (2016) Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. J Immunother Cancer 4:95|
|Wilcox, Ryan A (2016) A three-signal model of T-cell lymphoma pathogenesis. Am J Hematol 91:113-22|
|Polk, Avery; Lu, Ye; Wang, Tianjiao et al. (2016) Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia. Clin Cancer Res 22:6118-6128|
|Briski, Robert; Feldman, Andrew L; Bailey, Nathaniel G et al. (2015) Survival in patients with limited-stage peripheral T-cell lymphomas. Leuk Lymphoma 56:1665-70|
Showing the most recent 10 out of 13 publications